Investigational drug · Phase 3
B2227
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Schizophrenia.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "B2227"
First trial start
2026
Aug 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "B2227", any sponsor or status.
Conditions studied
As listed on its trial records.
- Schizophrenia
Approved drugs for the same conditions: Schizophrenia · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "B2227" as an intervention, largest first.
- A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With SchizophreniaPivotal-lookingNot yet recruiting
Bostal Drug Delivery Co., LtdIndustry
NCT07722728 · 84 participants (planned) · Start Aug 2026 · Primary completion Aug 2027
Drug: 30 mg B2227; 70 mg B2227 and 5 more · For: Schizophrenia
Newest research
PubMed records naming it or its code names, newest first.
- Oligomerization of Peptides LVEALYL and RGFFYT and Their Binding Affinity to Insulin.
Chiang HL, Ngo ST, Chen CJ, et al. · PLoS One 2013
Also in development for Schizophrenia
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- NBI-1117568Phase 35 trials
Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania
- LB-102Phase 34 trials
LB Pharmaceuticals Inc. · Schizophrenia, Bipolar I Disorder
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- OLZSAM, ALKS 3831Phase 32 trials
Alkermes, Inc. · Bipolar I Disorder, Schizophrenia
- ML-007C-MAPhase 24 trials
MapLight Therapeutics · Psychosis Associated With Alzheimer's Disease, Schizophrenia
- ALTO-101Phase 21 trial
Alto Neuroscience · Schizophrenia, Cognitive Impairment
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.